Risedronate Norwich-Eaton Pharmaceuticals Inc.
Risedronate (NE-58095) is a third generation bisphosphonate bone-resorption inhibitor and osteogenesis stimulator under development by Norwich-Eaton (a subsidiary of Procter and Gamble) for the potential treatment of various bone diseases including osteoporosis and Paget's disease. Risedronate's two-month regimen is shorter than that of the other oral bisphosphonates approved for Paget's disease--etidronate (Procter and Gamble Co), olendronate and tiludronate (Elf Sanofi). Risedronate is predicted to make a significant commercial impact [295049].